Why Sanara MedTech Inc.’s (SMTI) Stock Is Up 11.83%
As of Thursday, July 30, Sanara MedTech Inc.’s SMTI share price has surged by 11.83%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; BiFORM, an osteoconductive, bioactive, porous implant that allows bony ingrowth across the graft site and it can be used as a strip or molded into a putty to fill a bone defect; ACTIGEN Inductive Bone Matrix, a naturally derived, differentiated allograft matrix with robust handling properties; ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Commentary & Analysis
Why Sanara MedTech Inc.’s (SMTI) Stock Is Up 11.67%
As of Thursday, July 30, Sanara MedTech Inc.’s SMTI share price has surged by 11.67%, which has investors questioning if this is right time to sell.Omar Beirat
Why Sanara MedTech Inc.’s (SMTI) Stock Is Down 7.70%
As of Tuesday, July 14, Sanara MedTech Inc.’s SMTI share price has dipped by 7.70%, which has investors questioning if this is right time to buy.Michael Rose
Why Sanara MedTech Inc.’s (SMTI) Stock Is Up 5.90%
As of Friday, June 26, Sanara MedTech Inc.’s SMTI share price has surged by 5.90%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Sanara MedTech Inc.’s (SMTI) Stock Is Up 5.96%
As of Monday, June 15, Sanara MedTech Inc.’s SMTI share price has surged by 5.96%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | SMTI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $316.5 | $422.9 | 32% |
|
| Shares Out (Mil) | 8.7 | 41.4 | 19% |
|
| Institutional Ownership | 36.8% | 83.6% | 15% |
|
| Float (Mil) | 3.8 | 34.9 | 10% |
|
| Beta | 1.16 | 0.88 | 69% |
|
| Avg Daily Volume (000s) | 357 | 409 | 52% |
|
| Price Change (52-week) |
12.1% | 66.3% | 55% |
|
| Growth | SMTI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 45.9% | 11.9% | 95% |
|
| Net Income (5yr) | (53.6%) | (5.9%) | 6% |
|
| EPS (5yr) | (41.8%) | 10.4% | 5 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 15.7% | (16.2%) | 74% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | $0.020 | $0.180 | $0.540 | |
| Month Ago EPS | $0.020 | $0.180 | $0.540 | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | $0.020 | $0.180 | $0.540 | |
| Year/Year Chg | (140.0%) | (500.0%) | (1,522%) | |
| Financials | SMTI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $110 | $123 | 27% |
|
| Net Income (TTM) (Mil) | ($32) | ($9) | 20% |
|
| EPS (TTM) | ($3.683) | ($0.400) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | $6 | ($3) | 36% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $48 | $22 | 38% |
|
| Enterprise Value (Q1) (Mil) | $349 | $418 | 31% |
|
| Valuation | SMTI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 40.06 | 3.13 | 98% |
|
| P/E | na | 28.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.7 | na |
|
| Ratios | SMTI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 93.0% | 58.7% | 94% |
|
| Net Margin | (29.2%) | (6.9%) | 15% |
|
| ROA | (38.1%) | (12.3%) | 14% |
|
| ROE | (147.7%) | (12.3%) | 6% |
|
| Liabilities to Assets | 88.5% | 46.0% | 83% |
|
| F-Score | 6 | 4 | 67% |
|
Sanara MedTech Inc. did not pass any screens on 8/21/2026.
